MA-ECHOSENS
Echosens , a high-technology company offering the FibroScan® family of products, recognizes the importance of World Diabetes Day (WDD), Nov. 14 and the month of November as American Diabetes Month for bringing greater focus to the impact of Type 2 diabetes and its link to metabolic syndrome (MetS) and nonalcoholic fatty liver disease (NAFLD). MetS is a cluster of risk factors specific for cardiovascular disease, and NAFLD is the accumulation of liver fat in people who drink little or no alcohol. Obesity is the most frequently observed component of MetS.
“WWD, a three-year campaign to improve access to diabetes care and prevent diabetes, and the American Diabetes Month present opportunities to highlight how obesity increases the risk for Type 2 diabetes, liver disease, MetS and heart disease,” says Dominique Legros, Echosens Group CEO. “Fat in the liver can increase the risks of progression of prediabetes to overt disease. Once a patient has fatty liver disease, diabetes may become more difficult to control, making it critical to obtain an early diagnosis and introduce lifestyle changes to halt or reverse NAFLD.”
NAFLD has 70% prevalence among Type 2 diabetes patients, and people living with Type 2 diabetes and NAFLD are at a two-fold risk of all-cause mortality versus those living with Type 2 diabetes alone. In the United States, 36.5% of adults are obese, while another 32.5% of American adults are overweight. Globally, about 13% of the world’s adult population has obesity and about 39% are overweight, according to the World Health Organization’s most recent statistics.
FibroScan, a painless, non-invasive exam at the point of care can measure and monitor the amount of liver stiffness and detect NAFLD in its earliest stages when the individual may be asymptomatic. It can be used to rule out the need for further assessment, such as a painful liver biopsy, saving time and resources for people who don’t need further assessment.
“The good news is that even moderate weight loss can significantly reduce liver fat in patients with NAFLD and play an essential role in the prevention and treatment of Type 2 diabetes,” adds Dominique Legros. “This November, we urge everyone touched by the growing liver disease epidemic to help promote advocacy efforts throughout the year and confront diabetes as a critical global health issue.”
To learn more, read “Early Detection, Healthy Diet and Lifestyle Changes Critical for Addressing Metabolic Syndrome and Halting Progression of Liver Disease .”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140+ international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005001/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riyadh Declaration on the Future of Tourism Sets 50-Year Roadmap as UN Tourism 26th General Assembly Closes in Saudi Arabia11.11.2025 13:39:00 CET | Press release
The 26th session of the UN Tourism General Assembly concluded today with the adoption of the Riyadh Declaration on the Future of Tourism, a momentous step taken by member states toward enhanced cooperation over the next 50 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111034542/en/ 26th UN Tourism General Assembly The Declaration reaffirms the Kingdom’s leadership in global tourism and its position at the heart of major, industry-changing decisions, as the ground-breaking Declaration is poised to play a central role in advancing the 2030 Agenda for Sustainable Development, emphasizing sustainability, digital innovation, AI integration, and inclusive tourism economies. The Riyadh Declaration on the Future of Tourism is a shared roadmap to guide the sector’s next half-century around sustainability, inclusion and AI-powered innovation.It underscores strengthening international cooperation, resilience, and the empower
Prokarium Appoints Ibs Mahmood as Chief Executive Officer11.11.2025 13:06:00 CET | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford. “Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder canc
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma11.11.2025 13:00:00 CET | Press release
Promega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma. “This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with th
The International Swaps and Derivatives Association (ISDA) Endorses the Alignment of the Close-out Netting Regulation with International Standards11.11.2025 12:31:00 CET | Press release
The ISDA endorsed the Close-out Netting and related Collateral Arrangements Regulation adopted by the Capital Market Authority (CMA), which came into effect in July 2025, confirming its alignment with international standards. According to a statement published on ISDA's website, the Regulation adopted by the CMA was included within the scope of ISDA's legal opinions consistent with international derivatives agreements, signifying that the Kingdom of Saudi Arabia has become a jurisdiction supporting international netting legislation, strengthening the enforceability of such contracts at the international level. Mr. Raed Ibrahim Alhumaid, CMA Deputy of Market Institutions, explained that the Regulation approved four months ago was designed to regulate netting agreements and related financial collateral arrangements involving a Capital Market Institution. It aims to enhance the stability of the financial system and protect investors, contributing to the growth of investments in the capita
Picsart Expands Creative Platform With AI Products to Empower and Accelerate Vibe Design at Scale11.11.2025 11:00:00 CET | Press release
Picsart Assistant Creates Layered-Designs Through Natural ConversationPicsart Flows Enables Collaborative and Automated Creation on Infinite Canvas Picsart, the world’s leading digital creation platform with more than 2 billion downloads and used by 130 million monthly active users in more than 150 countries worldwide, today announced the expansion of its creative platform with AI products built to empower and accelerate vibe design at scale and simplify creative workflows. The announcement was made by Hovhannes Avoyan, Picsart co-founder and CEO, at Web Summit, one of the world’s largest technology conferences hosted annually in Lisbon, Portugal. Picsart enables a diverse set of creators to instantly bring their personal vision to life, offering more than 150 tools, millions of stickers, templates, UGC options, and premium stock content. Picsart is recognized for its engagement with the global Gen Z community, which represents more than 50% of its active user base. The company continu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom